BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoshikawa K, Naito T, Akutsu S, Saotome M, Maekawa Y, Kawakami J. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients. Basic Clin Pharmacol Toxicol 2020;126:353-63. [DOI: 10.1111/bcpt.13355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Naghedi A, Haghaninejad H, Varastehravan H, Naghedi A, Farshadi N. Effect of vitamin D supplements on left ventricular ejection fraction in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. Rev Port Cardiol (Engl Ed) 2021;40:447-55. [PMID: 34274087 DOI: 10.1016/j.repce.2021.07.010] [Reference Citation Analysis]
2 Akutsu S, Mino Y, Naito T, Hoshikawa K, Saotome M, Maekawa Y, Kawakami J. Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03341-y] [Reference Citation Analysis]
3 Naghedi A, Haghaninejad H, Varastehravan H, Naghedi A, Farshadi N. Effect of vitamin D supplements on left ventricular ejection fraction in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. Rev Port Cardiol 2021;40:447-55. [PMID: 34053778 DOI: 10.1016/j.repc.2020.10.014] [Reference Citation Analysis]
4 Lin YS, Thummel KE, Thompson BD, Totah RA, Cho CW. Sources of Interindividual Variability. Methods Mol Biol 2021;2342:481-550. [PMID: 34272705 DOI: 10.1007/978-1-0716-1554-6_17] [Reference Citation Analysis]